Efficacy of transoral outlet reduction in Roux-en-Y gastric bypass patients to promote weight loss: a systematic review and meta-analysis

Authors
Banreet Singh Dhindsa1, Syed Mohsin Saghir1, Yassin Naga1, Amaninder Dhaliwal2, Dayl Ramai2, Chad Cross3, Shailender Singh2, Ishfaq Bhat2, Douglas G. Adler5

Institutions
1 Department of Internal Medicine, University of Nebraska Medical Center, Las Vegas, Nevada, United States
2 Division of Gastroenterology and Hepatology, University of Nebraska Medical Center, Las Vegas, Nevada, United States
3 Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, New York, United States
4 Department of Biostatistics and Epidemiology, University of Nevada Las Vegas, Las Vegas, Nevada, United States
5 Gastroenterology and Hepatology, University of Utah School of Medicine, Huntsman Cancer Center, Salt Lake City, Utah

submitted 8.4.2020
accepted after revision 22.5.2020

ABSTRACT
Background and study aims Transoral outlet reduction (TORe) is an endoscopic procedure used in patients with weight gain post Roux-en-Y gastric bypass (RYGB). We performed a systematic review and meta-analysis to evaluate the efficacy and safety of TORe with a full-thickness suturing device for treating patients with weight regain after RYGB.

Patients and methods We conducted a comprehensive search of several databases and conference proceedings including PubMed, EMBASE, Google-Scholar, MEDLINE, SCOPUS, and Web of Science databases (earliest inception to March 2020). The primary outcomes assessed were technical success, absolute weight loss (AWL) and percent of total weight loss (% TWL) at 3, 6, and 12 months after the procedure. The secondary outcomes assessed were pooled rate of adverse events (AEs), adverse event subtypes and association of size of gastrojejunal anastomosis (GJA) and percent TWL.

Results Thirteen studies on 850 patients were included. The pooled rate of technical success was 99.89 %. The absolute weight loss (kg) at 3, 6, and 12 months was 6.14, 10.15, and 7.14, respectively. The percent TWL at 3, 6, and 12 months was 6.69, 11.34, and 8.55, respectively. The pooled rate of AE was 11.4 % with abdominal pain being the most common adverse event. The correlation coefficient (r) was –0.11 between post TORe GJA size and weight loss at 12 months.

Conclusion TORe is an endoscopic procedure that is safe and technically feasible for post RYGB with weight gain.

Introduction
Obesity is a growing global epidemic associated with increased morbidity and mortality [1]. Multiple comorbidities, including diabetes mellitus, cardiovascular disease, and stroke, are associated with obesity [2]. Bariatric surgery is the gold standard of care for effective sustainable weight reduction and has been shown to induce remission of diabetes mellitus and metabolic syndrome [3, 4]. Roux-en-Y gastric bypass surgery (RYGB) is a...
common form of effective bariatric surgery that leads to significant long term weight loss compared to sleeve gastrectomy or gastric banding [5].

Despite the efficacy of RYGB, some studies have noted weight regain or insufficient weight loss in a proportion of patients [3, 6]. Factors contributing to weight gain after RYGB include mechanical dehiscence of staples, dilation of the gastrojejunal anastomosis (GJA), and patient-related factors such as dietary noncompliance, physical inactivity, and mental health disorders [7, 8]. Due to the occurrence of weight gain, revision surgery after RYGB has become increasingly popular [9]. The American Society of Metabolic and Bariatric Surgery (ASMBS) estimates that incidence of patients requiring revision of prior bariatric surgeries has more than doubled in United States, increasing from 6% in 2011 to 15.4% in 2018 [10]. Currently, there is no established standard management for revisional surgery after RYGB. Options include gastric banding revision (which involves placement of a prosthetic band distal to the gastro-esophageal junction), conversion to a distal RYGB by taking down the jejunojejunostomy with creation of a reanastomosis to the ileum, biliopancreatic diversion/duodenal switch revision and endoluminal procedures such as transoral outlet reduction (TORe) [3].

TORe is a minimally invasive endoscopic surgery that reduces the size of the GJA to achieve weight loss through mechanical restriction [11, 12]. According to Abu Dayyah et al, the diameter of the GJA is a significant predictor of weight regain [13]. In 2014, TORe was first described as an endoscopic suturing procedure that reduces the size of the GJA [14]. This procedure has been performed using various techniques including plication devices (Stomaphyx; Endogastric Solutions, California, United States), suction based superficial suturing devices (Endocinch; C.R. Bard, Murray Hill, New Jersey, United States) or with the full thickness suturing devices (Overstitch; Apollo Endosurgery, Texas, United States) [15]. TORe initially demonstrated safety and efficacy with the suction-based superficial suturing system (Endocinch; C.R. Bard, Murray Hill, New Jersey, United States) [16]. Further developments with the full-thickness suturing system (Overstitch device) demonstrated superior durability and greater weight loss compared to the suction-based superficial system (Endocinch; C.R. Bard, Murray Hill, New Jersey, United States) [17]. The endoscopic gastric plication device (Stomaphyx; Endogastric Solutions, California, United States) did not demonstrate satisfactory weight loss [18]. TORe has shown promising results in a previous meta-analysis performed for all types of TORe procedures including plication devices, superficial suturing devices, Argon Plasma Coagulation (APC) and over-the-scope-clip (OTSC; Ovesco AG, Tubingen, Germany) [19]. Currently the full-thickness suturing device (Overstitch; Apollo Endosurgery, Texas, United States) with APC is the most commonly used device and this meta-analysis evaluated the efficacy and safety of TORe with this device as a therapeutic option for treating patients with weight regain after a RYGB.

Methods

Search strategy

We conducted a comprehensive search of several databases and conference proceedings including PubMed, EMBASE, Google-Scholar, MEDLINE, SCOPUS, and Web of Science databases (earliest inception to March 2020). We followed the Preferred Reporting items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, by using predefined protocol, to identify studies reporting on TORe in patients with weight regain after RYGB surgery (▶Fig. 1) [20]. MOOSE guidelines checklist and PRISMA checklist can be seen in Supplementary Fig. 1 and Supplementary Fig. 2 respectively.

Key words used in the literature search included a combination of ‘Transoral’, ‘outlet’, ‘reduction’, ‘Roux-en-Y’, ‘suture’, ‘gastric’ and ‘bypass’. The search was restricted to studies in human subjects in peer-reviewed journals. Two authors (BD, SS) independently reviewed the title and abstract of studies identified in primary search and excluded studies that did not
address the primary research question, based on pre-specified exclusion and inclusion criteria. The full text of the remaining articles was reviewed to determine whether they contained relevant information. Any discrepancy in article selection was resolved by consensus with a third author (YN).

The bibliographic section of the selected articles, as well as the systematic and narrative articles on the topic were manually searched for additional relevant articles.

**Study selection**

In this meta-analysis, we included studies that evaluated performance of a TORe procedure with a full-thickness suturing device (Overstitch; Apollo Endosurgery, Texas, United States) in patients with weight regain after RYGB surgery. Studies irrespective of inpatient/outpatient setting, geography, abstract/manuscript status, were included as long as they provided data needed for the analysis.

The following were our exclusion criteria: (1) alternative methods of TORe like StomaphyX (Endogastric Solutions, San Mateo, California), Bard Endocinch (C.R. Bard, Murray Hill, New Jersey); (2) studies with sample size < 10 patients; (3) studies performed in the pediatric population (age < 18 years); and (4) studies not in English language.

In cases of multiple publications from the same cohort and/or overlapping cohorts, data from the most recent and/or most appropriate comprehensive report were included.

**Data abstraction and quality assessment**

Data on study-related outcomes in the individual studies were abstracted onto a standardized form by at least three authors (BD, SS, AD), and two authors (BD, SS) did the quality scoring independently.

The collected data were treated akin to single group cohort studies, therefore, we used the Newcastle-Ottawa scale for cohort studies to assess the quality of studies [21]. Quality assessment for randomized controlled trials was done with Jadad-Oxford scale [22]. Details of quality assessment are provided in Table 1.

**Outcomes assessed**

The primary outcomes assessed were (a) technical success of TORe procedure with full thickness suturing device; (b) absolute weight loss at 3, 6, and 12 months after the procedure; and (c) percent of total weight loss (TWL) at 3, 6, and 12 months after the procedure.

The secondary outcomes assessed were (a) pooled rate of adverse events (AEs) of TORe procedure; (b) pooled rate of AE subtypes: abdominal pain, bleeding, perforation, stenosis; (c) association of size of GJA and percent TWL; and (d) subgroup analysis between prospective and retrospective studies for primary and secondary outcomes.

**Definitions**

Definition of outcomes:

Technical success of TORe procedure with full-thickness suturing device was defined in 7 studies. Four studies [12, 23–25]...
considered post procedure GJA size < 10 mm and four studies [26–29] considered post-procedure GJA size < 12 mm to be technically successful.

Absolute weight loss was calculated using the formula TORe weight - follow up weight and TWL was defined as (TORe weight - follow up weight)/TORe weight x 100 %.

AEs were defined as complications that were directly related to the procedure. AE were divided into mild, moderate, severe and fatal as per ASGE guidelines [30].

Statistical analysis

We used meta-analysis techniques to calculate the pooled estimates for each outcome of interest following the methods suggested by DerSimonian and Laird using the random-effects model where appropriate [31]. In several instances in the data, values of zero occurred. In these instances, we avoided inadvertently adding positive bias to the outcomes by writing syntax to calculate weighted summary statistics. In this way, we preserved the integrity of the actual data values and avoided possible biases in reporting the outcomes. We assessed heterogeneity between study-specific estimates by using Cochrane Q statistical test for heterogeneity, 95% prediction interval (PI), which deals with the dispersion of the effects, and the I² statistics [32, 33]. In this, values of < 30%, 30% to 60%, 61% to 75%, and > 75% were suggestive of low, moderate, substantial, and considerable heterogeneity, respectively [34]. Publication bias was ascertained, qualitatively, by visual inspection of funnel plot and quantitatively, by the LFK test; further, the extent of potential bias was ascertained utilizing the Doi Plot [35]. Sensitivity analysis was conducted in instances of potential bias by recalculating all statistics after removal of studies leading to LFK asymmetry; if removal of the study impacted estimates, the study was removed from the final analysis. Finally, we investigated potential correlative associations between post TORe GJA size and weight loss at 12 months using a study-based weighted correlation. All meta-analyses were performed using MetaXL software (v. 5.3; Epigear International), and the weighted correlation was calculated using R (v 3.6.1; Vienna, Austria) with the <wtd.cor> script in the "weight" package, with bootstrapped P values calculated with n = 10,000 iterations.

Results

Search results and population characteristics

From an initial 574 studies, thirteen studies reported use of TORe with full-thickness suturing device in RYGB patients. In our search process, we encountered multiple studies that had overlapping cohorts. The most comprehensive studies were included in the final analysis. The schematic diagram of study selection is illustrated in ▶ Fig. 1.

The majority of patients were females. The indication for TORe procedure was weight gain after RYGB. All studies used the full-thickness suturing device.

Characteristics and quality of included studies

The meta-analysis included 13 independent cohort studies with total of 850 patients and 877 TORe procedures were performed on these patients.

None of the studies were population-based. Two studies were multicenter, and 11 studies were from a single center. Six studies had more than 40 patients, four studies had more than 20 patients, and three studies had less than 20 patients. All of

| Study          | Year | Country | Single/Multicenter | Manuscript/Abstract | No. of patients | No. of procedures | Tech. Success | Mean age | Males | Females |
|----------------|------|---------|--------------------|---------------------|-----------------|-------------------|---------------|----------|-------|---------|
| Jirapinyo [37] | 2020 | USA     | Single             | Manuscript          | 331             | 342               | 342           | 50       | 47    | 284     |
| Callahan [23]  | 2019 | USA     | Single             | Manuscript          | 70              | 70                | 70            | 51.3     | 7     | 63      |
| Kothari [42]   | 2018 | USA     | Single             | Abstract            | 10              | 10                | 10            | 52.6     | 1     | 9       |
| Staudenmann [25]| 2017 | Switzerland | Single             | Abstract            | 22              | 22                | 22            | –        | –     | –       |
| Tsai [36]      | 2018 | Switzerland | Single             | Manuscript          | 81              | 97                | 97            | 48       | 22    | 59      |
| Vargas [12]    | 2017 | USA     | Multicenter        | Manuscript          | 130             | 130               | 130           | 47.12     | 16    | 114     |
| Catalano [43]  | 2016 | USA     | Single             | Abstract            | 29              | 29                | 29            | –        | 5     | 24      |
| Espinet [26]   | 2018 | Spain   | Multicenter        | Manuscript          | 13              | 13                | 13            | 50       | 5     | 8       |
| Fayad [27]     | 2019 | USA     | Single             | Manuscript          | 44              | 44                | 43            | –        | –     | –       |
| Goyal [24]     | 2016 | USA     | Single             | Manuscript          | 40              | 40                | 40            | 53       | 9     | 31      |
| Hollenbach [28]| 2019 | Germany | Single             | Manuscript          | 26              | 26                | 26            | –        | –     | –       |
| Laterza [44]   | 2017 | Italy   | Single             | Abstract            | 35              | 35                | 35            | –        | –     | –       |
| Brunaldi [29]  | 2020 | Brazil  | Single             | Manuscript          | 19              | 19                | 19            | 45.8     | –     | –       |
the studies included had clear information reporting on the technical success, AE rates, including the sub-category of the AE. Five, six, and eight studies reported on 3-, 6-, and 12-month weight loss outcomes, respectively. Two studies reported 5-year weight loss outcomes. Nine studies were published in manuscript (peer reviewed) form and four studies were in abstract form. Eight studies were retrospective cohort studies, four were prospective cohort studies and one study was a randomized controlled trial.

Table 1 and Table 2 describe the characteristics of the included studies and the study quality assessment, respectively.

Meta-analysis outcomes

Primary outcomes

The calculated pooled rate of technical success was 99.89% (± 3.52%).

The absolute weight loss at 3, 6, and 12 months was 6.14 kg (95% CI 4.27–8.73, I² = 89%, PI = 0.84 to 13.11), 10.15 kg (95% CI 7.71–12.58, I² = 93%, PI = 1.54 to 18.74) and 7.14 kg (95% CI 6.42–9.67, I² = 99%, PI = 2 to 16.29), respectively.

The percent TWL at 3, 6, and 12 months was 6.69% (95% CI 3.82–9.55%, I² = 98%, PI = –3.87 to 17.2), 11.34% (95% CI 8.07–14.67, I² = 94%, PI = –0.09 to 23.67) and 8.55% (95% CI 5.69–11.4, I² = 99%, PI = 1.67 to 18.77), respectively.

Fig. 2 and Fig. 3 show the forest plots for absolute weight loss and percent total weight loss, respectively.

![Fig. 2](https://example.com/fig2.png)

![Fig. 3](https://example.com/fig3.png)
Secondary outcomes
The calculated pooled rate of AEs was 11.4 % (±10.11) with abdominal pain being the most common adverse event at 4.22 % (±8). Table 3 describes the AEs in different studies. The calculated pooled rate of mild, moderate, and severe AEs was 4.56 % (±5.45 %), 1.6 % (±1.65 %) and 0.57 % (±1.35 %), respectively. Subgroup analysis could be only performed for AEs and showed an overall lower rate of AEs for prospective studies (7.78 % ± 7.46 %) compared to retrospective studies (12.25 % ± 10.81 %). The correlation coefficient (r) was −0.11 (t = −3.63; P < 0.001) between post TORe GJA size and weight loss at 12 months.

Validation of meta-analysis results
Sensitivity analysis
To assess whether any one study had a dominant effect on the meta-analysis, we excluded one study at a time and analyzed its effect on the main summary estimate. On this analysis, no single study significantly affected the outcome or the heterogeneity.

Heterogeneity
We assessed heterogeneity using the I² percentage values and prediction intervals (PI). Substantial heterogeneity with wide PI was noted in the analysis of absolute weight reduction and percent TWL at 3, 6, and 12 months.

▶Fig. 3 Forest plots showing percent total weight loss at 3, 6, and 12 months.
Publication bias

Based on visual inspection of the funnel plot and the Doi Plot, as well as quantitative measurement based on the LFK test, there was evidence of asymmetry and hence potential publication bias. Sensitivity analysis by removal of asymmetric studies revealed the impact of the possible publication bias but this did not lead to a statistical change in the calculated estimate or the conclusion of this meta-analysis. However, it should be noted that the ability to detect bias is limited.

Discussion

Our study demonstrates that TORe is an alternative minimally invasive surgical treatment for patients with weight gain following RYBG. TORe showed a high technical success and a low adverse event rate. To our knowledge, this is the first meta-analysis of the commercially available full thickness suturing device for patients with weight gain after RYGB.

In our meta-analysis, we analyzed % TWL and absolute weight loss at 3, 6, and 12 months. Our pooled percent TWL and AWL at 3 and 6 months showed persistent weight loss. At the 12-month mark there was evidence of weight recidivism from 11.34 % TWL at 6 months to 8.55 %. Two studies [24, 36] showed persistent weight loss and the rest of the studies demonstrated weight recidivism at 12 months. It is hypothesized that the weight loss post TORe was secondary to reduction in GJA size, improved eating habits, quicker gastric emptying times, and induction of satiety by stimulating gastric stretch receptors [11, 24, 27, 28]. Weight recidivism was reported to be due to genetic factors, lack of dietary compliance, or due to suture breakage/migration leading to dilation of the GJA after TORe [26–28, 36].

Long-term outcomes (5 years) were reported in two studies [23, 37]. Callahan et al exhibited weight recidivism in their long-term analysis of TORe. In subgroup analysis of different suture types in this study, the pursestring suture group showed weight loss while the interrupted suture group showed weight recidivism [23]. Jirapinyo et al showed persistent weight loss and the majority of the patients in this study underwent purse-string suturing. Many patients in this study also underwent repeat procedures and received other adjunctive therapies once they attained a weight plateau or had minimal benefit (<5 % TWL) [37].

In 850 patients, AE rates were 11.4 % (± 10.11) without any mortality. This is comparable to other revisional procedures such as adjustable gastric banding and distal RYGB conversion [38–40]. The most common AE in our study was abdominal pain at 4.22 % (± 8). Rates of perforation and bleeding were low at 0.46 % (± 1.16) and 1.14 % (±1.38), respectively. This signifies that TORe is a safe procedure if performed by an endoscopist trained in endoscopic suturing.

Post TORe GJA size was weakly related to the percent TWL with r value of -0.1 (P<0.001), which indicates there might be increased weight loss with smaller GJA size. However, according to Jirapinyo et al, there was an increased incidence of nausea and vomiting with GJA < 4 mm [37]. The majority of the studies aimed for a GJA size < 10–12 mm [12, 23–27, 29, 36].

Strengths of this procedure surround the minimally invasive aspect of it and subsequent weight loss observed from doing so. The two studies with over 1-year follow-up show that this procedure may be durable for long-term weight loss. Areas of interest involve the different types of suture styles with the Apollo device and how they affect patients in the long run. Currently, pursestring sutures may provide the best results for sustained weight loss [23, 27, 36, 37].

---

Table 3 Adverse events in all procedures.

| Study          | Year | Total adverse events | Bleeding | Perforation | Abdominal pain | Stenosis | Others |
|----------------|------|----------------------|----------|-------------|----------------|----------|--------|
| Jirapinyo [37] | 2020 | 35                   | 6        | 0           | 8              | 2        | 19     |
| Callahan [23]  | 2019 | 4                    | 2        | 1           | 0              | 0        | 1      |
| Kothari [42]   | 2018 | 2                    | 0        | 0           | 0              | 0        | 2      |
| Staudenmann [25]| 2017 | 1                    | 0        | 1           | 0              | 0        | 0      |
| Tsai [36]      | 2018 | 0                    | 0        | 0           | 0              | 0        | 0      |
| Vargas [12]    | 2017 | 41                   | 0        | 0           | 23             | 0        | 18     |
| Catalano [43]  | 2016 | 6                    | 0        | 0           | 6              | 0        | 0      |
| Espinet [26]   | 2018 | 3                    | 1        | 0           | 0              | 0        | 2      |
| Fayad [27]     | 2019 | 3                    | 0        | 0           | 0              | 0        | 3      |
| Goyal [24]     | 2016 | 0                    | 0        | 0           | 0              | 0        | 0      |
| Hollenbach [28]| 2019 | 1                    | 0        | 1           | 0              | 0        | 0      |
| Laterza [44]   | 2017 | 3                    | 1        | 1           | 0              | 0        | 1      |
| Brunaldi [29]  | 2020 | 1                    | 0        | 0           | 0              | 1        | 0      |
Two studies have compared TORe with APC to TORe with ESD [28, 41]. One study reported greater weight loss with ESD-TORe as compared to TORe with APC while the other study did not reveal any significant difference between the two groups. This is another novel addition to TORe and more studies are needed to evaluate its safety and efficacy.

Limitations include some of the studies being retrospective in nature, most of the studies had short-term follow-up, and there was loss of follow-up. Our pooled rates were limited by heterogeneity and there was increased risk of confounding bias due to majority of the studies being retrospective. For unexperienced endoscopists, this procedure may be technically challenging and thus affect generalizability. More long-term studies should be done to observe durability as seen in the reports from Callahan and Jirapinyo et al. Future studies should include follow-up endoscopy post TORe to examine the GJA to evaluate its durability and to see if this correlates with weight recidivism after TORe is done.

Conclusion
In conclusion, TORe is a minimally invasive procedure that may be safe and feasible for post RYGB patients who do not want to undergo a surgical revision due to increased morbidity and mortality. TORe shows promising results in the short term, but more studies are needed to evaluate long-term success of this procedure.

Competing interests
The authors declare that they have no conflict of interest.

References

[1] Afshin A, Forouzanfar MH. GBD 2015 Obesity Collaborators. et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017; 377: 13–27
[2] Smith KB, Smith MS. Obesity statistics. Primary care 2016; 43: 121–135, ix
[3] Tran DD, Nwokeabia ID, Purnell S et al. Revision of Roux-En-Y gastric bypass for weight regain: a systematic review of techniques and outcomes. Obes Surg 2016; 26: 1627–1634
[4] Gloy VL, Briel M, Bhatt DL et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 347: f5934
[5] Maciejewski MT, Arterburn DE, Van Scoyoc L et al. Bariatric Surgery and long-term durability of weight loss. JAMA Surg 2016; 151: 1046–1055
[6] King WC, Hinerman AS, Belle SH et al. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. JAMA 2018; 320: 1560–1569
[7] Changela K, Ofori E, Duddempudi S et al. Peroral endoscopic reduction of dilated gastrojejunal anastomosis after bariatric surgery: Techniques and efficacy. World J Gastrointest Endosc 2016; 8: 239–243
[8] Karmali S, Brar B, Shi X et al. Weight recidivism post-bariatric surgery: a systematic review. Obes Surg 2013; 23: 1922–1933
[9] Hourneaux De Moura DT, Thompson CC. Endoscopic management of weight regain following Roux-en-Y gastric bypass. Expert Rev Endocrinol Metab 2019; 14: 97–110
[10] American Society for Metabolic and Bariatric Surgery. Estimate of Bariatric surgery numbers, 2011–2018. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers
[11] Jirapinyo P, Dayyeh BK, Thompson CC. Gastrojejunal anastomotic reduction for weight regain in roux-en-y gastric bypass patients: physiological, behavioral, and anatomical effects of endoscopic suturing and sclerotherapy. Surg Obes Relat Dis 2016; 12: 1810–1816
[12] Vargas Ej, Bazerbachi F, Rizk M et al. Transoral outlet reduction with full thickness endoscopic suturing for weight regain after gastric bypass: a large multicenter international experience and meta-analysis. Surg Endosc 2018; 32: 252–259
[13] Abu Dayyeh BK, Lautz DB, Thompson CC. Gastrojejunal stoma diameter predicts weight regain after Roux-en-Y gastric bypass. Clin Gastroenterol Hepat 2011; 9: 228–233
[14] Thompson CC, Slattery J, Bundga ME et al. Peroral endoscopic reduction of dilated gastrojejunal anastomosis after Roux-en-y gastric bypass: a possible new option for patients with weight regain. Surg Endosc 2006; 20: 1744–1748
[15] Wong SKH. Endoscopic full-thickness transoral outlet reduction with endoscopic submucosal dissection or argon plasma coagulation: does it make a difference? Endoscopy 2019; 51: 617–618
[16] Watson RR. The use of the Overstitch for bariatric weight loss. Gastrointest Endosc Clin N Am 2020; 30: 115–128
[17] Kumar N, Thompson CC. Comparison of a superficial suturing device with a full-thickness suturing device for transoral outlet reduction (with videos). Gastrointest Endosc 2014; 79: 984–989
[18] Eid GM, McCloskey CA, Eagleton JK et al. StomaphyX vs a sham procedure for revisional surgery to reduce regained weight in Roux-en-Y gastric bypass patients: a randomized clinical trial. JAMA Surg 2014; 149: 372–379
[19] Brunaldi VO, Jirapinyo P, de Moura DTH et al. Endoscopic Treatment of weight regain following Roux-en-Y gastric bypass: a systematic review and meta-analysis. Obes Surg 2018; 28: 266–276
[20] Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals Internal Med 2009; 151: 264–269
[21] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–605
[22] Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12
[23] Callahan ZM, Su B, Kuchta K et al. Five-year results of endoscopic gastrojejunoanostomysis revision (transoral outlet reduction) for weight gain after gastric bypass. Surg Endosc 2019: doi:10.1007/s00464-019-07003-6
[24] Goyal D, Kim S, Dutson E et al. Endoscopic trans-oral outlet reduction in combination with gastroplasty (TORe-G) is a novel technique that is highly efficacious and safe for weight loss in patients with failed Roux-en-Y gastric bypass (RYGB). American Journal of Gastroenterology 2015; 110: S565–S567
[25] Staudemann D, Gass M, Milone C et al. Transoral outlet reduction (TORe) partially reverses weight regain after bariatric Roux-en-Y gastric bypass (RYGB). First clinical experience from a tertiary referral center. Muttenz, Switzerland: Emh Swiss Medical Publishers Ltd Farnsburgerstr 8; Ch-4132 2S
[26] Espinet-Coll E, Nebreda-Durán J, López-Nava-Breviere G et al. Eficacia y seguridad del TORe mediante sutura endoscopica para tratar la reganancia ponderal tras bypass gástrico quirúrgico en Y-de-Roux. Re vista Española de Enfermedades Digestivas 2018; 110: 551–556
[27] Fayad L, Schweitzer M, Raad M et al. A real-world, insurance-based algorithm using the two-fold running suture technique for transoral outlet reduction for weight regain and dumping syndrome after Roux-En-Y gastric bypass. Obes Surg 2019; 29: 2225–2232

[28] Hollenbach M, Selig L, Lellwitz S et al. Endoscopic full-thickness transoral outlet reduction with semicircumferential endoscopic submucosal dissection. Endoscopy 2019; 51: 684–688

[29] Brunaldi VO, Ayala Farias CF, Tavares de Rezende D et al. Argon plasma coagulation alone versus endoscopic suturing plus argon plasma coagulation to treat weight regain after Roux-en-Y gastric bypass: a prospective randomized trial (with videos). Gastrointest Endosc 2020; doi:10.1016/j.gie.2020.03.3757

[30] Cotton PB, Eisen GM, Aabakken L et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446–454

[31] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188

[32] Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560

[33] Kanwal F, White D. “Systematic Reviews and Meta-analyses” in clinical gastroenterology and hepatology. Clin Gastroenterol Hepatol 2012; 10: 1184–1186

[34] Guyatt GH, Oxman AD, Kunz R et al. GRADE guidelines: 7. Rating the quality of evidence – inconsistency. J Clin Epidemiol 2011; 64: 1294–1302

[35] Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc 2018; 16: 195–203

[36] Tsai C, Steffen R, Kessler U et al. Endoscopic gastrojejunal revisions following gastric bypass: lessons learned in more than 100 consecutive patients. J Gastrointest Surg 2019; 23: 58–66

[37] Jirapinyo P, Kumar N, AlSamman MA et al. Five-year outcomes of transoral outlet reduction for the treatment of weight regain after Roux-en-Y gastric bypass. Gastrointest Endosc 2019: doi:10.1016/j.gie.2019.11.044

[38] Chang SH, Stoll CR, Song J et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg 2014; 149: 275–287

[39] Ghias S, Higa K, Chang S et al. Conversion of standard Roux-en-Y gastric bypass to distal bypass for weight loss failure and metabolic syndrome: 3-year follow-up and evolution of technique to reduce nutritional complications. Surg Obes Relat Dis 2018; 14: 554–561

[40] Shimizu H, Annaberdyev S, Motamarry I et al. Revisional bariatric surgery for unsuccessful weight loss and complications. Obes Surg 2013; 23: 1766–1773

[41] Jirapinyo P, de Moura DTH, Thompson CC. Endoscopic submucosal dissection with suturing for the treatment of weight regain after gastric bypass: outcomes and comparison with traditional transoral outlet reduction (with video). Gastrointest Endosc 2020; doi:10.1016/j.gie.2020.01.036

[42] Kothari T, Kaul V, Bittner KE et al. Outcomes of a Transoral Outlet Reduction Endoscopy Procedure for Weight Regain Due to Dilated Anastomosis Aperture in Roux-en-Y Patients: 1024. American Journal of Gastroenterology 2018; 113: 582–583

[43] Catalano MF, Khan NM, Lajin M et al. Mo2005 Gastric Outlet Revision Using Endoscopic Suturing (ES) in Patients Presenting With Weight Regain Following Roux-en-Y Gastric Bypass (RYGB). Gastrointestinal Endoscopy 2016; 83: A8491

[44] Laterza L, Boskoski I, Landi R et al. Transoral Outlet Reduction for Therapy of Weight Regain After Gastric Bypass: 770. American Journal of Gastroenterology 2017; 112: S430–S431